RxDoctor Payments Data

Julius Debroeck, MD

Family Medicine · Cypress, TXNPI 1023180429

Payments from drug & device makers

$8,751in general payments, 2019–2025

Across 482 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • AstraZeneca$926
  • Boehringer Ingelheim$657
  • Pfizer$604
  • Lilly USA, LLC$532
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,69599%
  • Education$561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk61$1,075
AbbVie(2 entities)66$1,047
AstraZeneca43$926
Boehringer Ingelheim31$657
Pfizer40$604
Lilly USA, LLC30$532
Takeda Pharmaceuticals U.S.A., Inc.18$374
Amgen16$322
Biohaven Pharmaceuticals, Inc.7$196
Abbott9$172
GSK8$155
Johnson & Johnson8$151
Bayer10$149
Corium, LLC7$145
Inspire Medical Systems, Inc.2$142
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$130
IBSA Pharma Inc.7$110
Adlon Therapeutics L.p.6$106
Otsuka America Pharmaceutical, Inc.5$106
Merck6$89
Biohaven Pharmaceutical Holding Company Ltd.3$86
Sunovion Pharmaceuticals Inc.6$84
Exact Sciences5$83
Antares Pharma, Inc.5$78
Scilex Pharmaceuticals Inc.5$77
Shire North American Group Inc4$68
Amarin Pharma, Inc.3$62
Endo Pharmaceuticals Inc.3$57
Ironshore Pharmaceuticals Inc.3$56
Avanir Pharmaceuticals, Inc.4$56
Hikma Pharmaceuticals USA3$50
Mylan Specialty L.p.3$49
Idorsia Pharmaceuticals US Inc3$48
Medtronic(2 entities)2$46
Eisai Inc.3$43
Amneal Pharmaceuticals LLC3$39
Bausch Health US, LLC3$38
Aytu Biopharma, Inc.1$37
Hologic Sales And Service, LLC2$34
Genentech USA, Inc.2$34
Edwards Lifesciences1$34
Astellas Pharma US Inc2$32
Sanofi-aventis U.S. LLC2$31
Vertical Pharmaceuticals, LLC2$31
Nestle Healthcare Nutrition Inc.2$30
Novartis2$29
Supernus Pharmaceuticals, Inc.2$27
Dexcom, Inc.2$26
United Therapeutics Corporation1$21
Corcept Therapeutics1$21
Lupin Inc.1$19
Vivus LLC1$19
Halozyme Inc1$17
Cranial Technologies, Inc1$17
Braintree Laboratories, Inc.1$16
Sanofi Pasteur Inc.1$15
Teva Pharmaceuticals USA, Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
Strongbridge US Inc.1$13
Clarus Therapeutics Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,751 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$152,481
Medicare patients
459
Services billed
3,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$109,236
JanuviaSitagliptin Phosphate51$64,441
JardianceEmpagliflozin37$54,999
FarxigaDapagliflozin Propanediol48$51,143
RybelsusSemaglutide35$45,248
TradjentaLinagliptin19$27,368
EliquisApixaban41$24,263
InvokanaCanagliflozin23$22,353
LinzessLinaclotide28$15,243
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,386
MyrbetriqMirabegron16$12,321
Breo ElliptaFluticasone/Vilanterol16$11,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,228
SynthroidLevothyroxine Sodium90$8,586
VascepaIcosapent Ethyl19$7,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,075$154,484127 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$657$87,81167 claims
MerckJanuvia$89$64,44151 claims
AstraZenecaFarxiga, Breztri Aerosphere$926$63,52961 claims
PfizerEliquis$604$24,26341 claims
AbbVieLinzess, Synthroid$1,047$23,828118 claims
Johnson & JohnsonInvokana$151$22,35323 claims
GSKBreo Ellipta, Trelegy Ellipta$155$20,41728 claims
Astellas Pharma US IncMyrbetriq$32$12,32116 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$39$6,319568 claims
IBSA Pharma Inc.Tirosint$110$1,60811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →